Published • loading... • Updated
Harvard Doctors See No Birth Defect Spike From Ozempic, Still Flash Caution Light
Summary by Hoodline
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Harvard Doctors See No Birth Defect Spike From Ozempic, Still Flash Caution Light
A new Harvard analysis is offering some cautious relief for people who stayed on GLP-1 weight-loss drugs such as semaglutide in very early pregnancy. The study found that continuing these medications into the first trimester did not appear to increase the risk of major birth defects or several other common adverse outcomes. The findings are reassuring for patients who were unknowingly exposed, though they do not rule out the possibility of rarer…
·United States
Read Full ArticleCoverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
